ROSE 010

Drug Profile

ROSE 010

Alternative Names: GTP-010; LY-307161 SR; ROSE-010

Latest Information Update: 21 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Rose Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides; Peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyspepsia; Irritable bowel syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 22 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Irritable bowel syndrome presented at the 16th United European Gastroenterology Week (UEGW-2008)
  • 22 May 2008 Final efficacy data from a phase II trial in Irritable bowel syndrome presented at Digestive Disease Week 2008 (DDW-2008)
  • 13 Oct 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top